Baloxavir Marboxil: An Original New Drug against Influenza
Baloxavir marboxil is a new drug developed in Japan by Shionogi to treat seasonal flu infection. This cap-dependent endonuclease inhibitor is a prodrug that releases the biologically active baloxavir acid. This new medicine has been marketed in Japan, the USA and Europe. It is well tolerated (more t...
| 發表在: | Pharmaceuticals |
|---|---|
| 主要作者: | |
| 格式: | Article |
| 語言: | 英语 |
| 出版: |
MDPI AG
2021-12-01
|
| 主題: | |
| 在線閱讀: | https://www.mdpi.com/1424-8247/15/1/28 |
| _version_ | 1850334871690412032 |
|---|---|
| author | François Dufrasne |
| author_facet | François Dufrasne |
| author_sort | François Dufrasne |
| collection | DOAJ |
| container_title | Pharmaceuticals |
| description | Baloxavir marboxil is a new drug developed in Japan by Shionogi to treat seasonal flu infection. This cap-dependent endonuclease inhibitor is a prodrug that releases the biologically active baloxavir acid. This new medicine has been marketed in Japan, the USA and Europe. It is well tolerated (more than 1% of the patients experienced diarrhea, bronchitis, nausea, nasopharyngitis, and headache), and both influenza A and B viruses are sensitive, although the B strain is more resistant due to variations in the amino acid residues in the binding site. The drug is now in post-marketing pharmacovigilance phase, and its interest will be especially re-evaluated in the future during the annual flu outbreaks. It has been also introduced in a recent clinical trial against COVID-19 with favipiravir. |
| format | Article |
| id | doaj-art-886e31a0ea72437e9cf1e61ba46d63fc |
| institution | Directory of Open Access Journals |
| issn | 1424-8247 |
| language | English |
| publishDate | 2021-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| spelling | doaj-art-886e31a0ea72437e9cf1e61ba46d63fc2025-08-19T23:16:41ZengMDPI AGPharmaceuticals1424-82472021-12-011512810.3390/ph15010028Baloxavir Marboxil: An Original New Drug against InfluenzaFrançois Dufrasne0Unité de Microbiologie, Chimie Bioorganique et Macromoléculaire, Département de Recherche et Développement du Médicament, Faculté de Pharmacie, Campus Plaine CP 205/5, Université Libre de Bruxelles, 1050 Brussels, BelgiumBaloxavir marboxil is a new drug developed in Japan by Shionogi to treat seasonal flu infection. This cap-dependent endonuclease inhibitor is a prodrug that releases the biologically active baloxavir acid. This new medicine has been marketed in Japan, the USA and Europe. It is well tolerated (more than 1% of the patients experienced diarrhea, bronchitis, nausea, nasopharyngitis, and headache), and both influenza A and B viruses are sensitive, although the B strain is more resistant due to variations in the amino acid residues in the binding site. The drug is now in post-marketing pharmacovigilance phase, and its interest will be especially re-evaluated in the future during the annual flu outbreaks. It has been also introduced in a recent clinical trial against COVID-19 with favipiravir.https://www.mdpi.com/1424-8247/15/1/28baloxavir marboxilinfluenzabaloxavir acidprodrugcap-dependent endonucleaseXofluza |
| spellingShingle | François Dufrasne Baloxavir Marboxil: An Original New Drug against Influenza baloxavir marboxil influenza baloxavir acid prodrug cap-dependent endonuclease Xofluza |
| title | Baloxavir Marboxil: An Original New Drug against Influenza |
| title_full | Baloxavir Marboxil: An Original New Drug against Influenza |
| title_fullStr | Baloxavir Marboxil: An Original New Drug against Influenza |
| title_full_unstemmed | Baloxavir Marboxil: An Original New Drug against Influenza |
| title_short | Baloxavir Marboxil: An Original New Drug against Influenza |
| title_sort | baloxavir marboxil an original new drug against influenza |
| topic | baloxavir marboxil influenza baloxavir acid prodrug cap-dependent endonuclease Xofluza |
| url | https://www.mdpi.com/1424-8247/15/1/28 |
| work_keys_str_mv | AT francoisdufrasne baloxavirmarboxilanoriginalnewdrugagainstinfluenza |